- Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Year 2023 -- Cabozantinib Franchise Achieved $1,629 million in U.S. Net Product Revenues for the Fiscal Year 2023, including $429 million for the Fourth Quarter of 2023 -- GAAP Diluted EPS of $0.27 for the Fourth Quarter o...

Related Keywords

United States , New York , American , Michaelm Morrissey , Susan Hubbard , Chris Senner , Gail Eckhardt , Maryc Beckerle , Takeda Pharmaceutical Company , International Kidney Cancer Symposium , Extensive Drug Development , Exelixis Inc , College Danl Duncan Comprehensive Cancer Center , Prostate Cancer Clinical Trials Working Group , Drug Administration , National Cancer Institute , Share Repurchase Program , Oncological Sciences , American Society Of Clinical Oncology , Arcus Biosciences Inc , Alliance For Clinical Trials In Oncology , University Of Utah , Translational Research , Nasdaq , Huntsman Cancer Institute , European Society For Medical Oncology , Fourth Quarter , Fiscal Year , Franchise Achieved , Product Revenues , Webcast Today , Chief Executive Officer , Investigational New Drug , Ipsen Pharma , Accepted Accounting Principles , Franchise Net Product Revenues , Trial Evaluating Cabozantinib , Advanced Pancreatic , Extra Pancreatic Neuroendocrine Tumors , Medical Oncology , Clinical Trials , Safety Monitoring Board , Metastatic Castration Resistant Prostate Cancer , American Society , Clinical Oncology , Cancers Symposium , Year Follow Up Results , Previously Untreated Renal Cell Carcinoma , Encouraging Results , Expansion Cohort , Evaluating Zanzalintinib , Advanced Kidney Cancer , Arcus Biosciences , Enter Clinical Trial Collaboration , Evaluate Zanzalintinib , Trial Evaluating Zanzalintinib , Previously Untreated Recurrent , Metastatic Head , Provides Strategic Review , Small Molecule Pipeline , Event Calendar , Two New Board Members , Corporate Governance , Exelixis Board , Distinguished Professor , Associate Dean , Experimental Therapeutics , Baylor College , Associate Director , Comprehensive Cancer , Key Priorities , Anticipated Milestones , Abbreviated New Drug Application , Investigational New Drug Applications ,